Artificial intelligence in Prechtl's General Movements Assessment: A systematic review and meta-analysis.

J Neonatal Perinatal MedMar 25, 2026 (epub)
Clinical ResearchPediatricsNeurology

Zhanna Zhussupova, Amin Tamadon, Natalya Chagay et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed AI-assisted Prechtl General Movements Assessment (GMA) for predicting later cerebral palsy (CP) and classifying expert-rated GMA labels. Of 105 studies in the qualitative synthesis, 28 contributed to quantitative analyses. Pooled diagnostic accuracy for CP outcomes was 0.884 (95% CI: 0.838-0.918), while pooled classification accuracy for expert-rated labels was 0.848 (95% CI: 0.761-0.908). The authors reported substantial heterogeneity and very low certainty because of heterogeneity and risk of bias, limiting confidence in the pooled estimates.

Key findings

  • Across 17 CP diagnosis outcome studies, pooled diagnostic accuracy was 0.884 (95% CI: 0.838-0.918).
  • Across 11 expert GMA label outcome studies, pooled classification accuracy was 0.848 (95% CI: 0.761-0.908).
  • Heterogeneity was substantial, and the authors judged certainty very low because of heterogeneity and risk of bias.
  • No GM developmental phase or sensor modality showed clear superiority.

Why it matters

AI-assisted GMA may help make movement assessment more objective and scalable, including where access to specialist expertise is limited. However, substantial variation between studies and risk of bias mean the pooled accuracy estimates should not be treated as established performance in routine settings. Standardized protocols, high-quality datasets, and transparent validation are important for assessing its clinical potential.

What to keep in mind

The review reports substantial heterogeneity and risk of bias, resulting in very low certainty; only 28 of 105 studies were included in quantitative synthesis.

Source

Published in J Neonatal Perinatal Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.